WESPAC Advisors SoCal’s Endocyte, Inc. Common Stock ECYT Stock Holding History

WESPAC Advisors SoCal’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$3K	–	380
2018 Q3	$3K	Buy	+200	New	+$3.43K	﹤0.01%	279
2018 Q2	–	Sell	-200	Closed	-$1K	–	286
2018 Q1	$1K	Hold	200	–	–	﹤0.01%	265
2017 Q4	$0	Buy	+200	New	+$953	﹤0.01%	297

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

WESPAC Advisors SoCal's ECYT Position: Q4 2018 in Review

WESPAC Advisors SoCal sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 200 shares — an estimated $3K sold.

WESPAC Advisors SoCal first reported a position in ECYT in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

WESPAC Advisors SoCal reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
WESPAC Advisors SoCal sold 200 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $3K.
WESPAC Advisors SoCal first reported a position in Endocyte, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
WESPAC Advisors SoCal's Endocyte, Inc. Common Stock position peaked at $3K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on WESPAC Advisors SoCal's 13F filing for Q4 2018, filed 7 Feb 2019.